3-D Matrix Ltd
TSE:7777
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
3-D Matrix Ltd
Capital Expenditures
3-D Matrix Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
3
|
3-D Matrix Ltd
TSE:7777
|
Capital Expenditures
-¥29.4m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
9%
|
|
|
SanBio Co Ltd
TSE:4592
|
Capital Expenditures
-¥3.9m
|
CAGR 3-Years
51%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Capital Expenditures
-¥1.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-19%
|
|
|
PeptiDream Inc
TSE:4587
|
Capital Expenditures
-¥1.8B
|
CAGR 3-Years
24%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-3%
|
|
|
Takara Bio Inc
TSE:4974
|
Capital Expenditures
-¥13B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-14%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Capital Expenditures
-¥3m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
3-D Matrix Ltd
Glance View
3-D Matrix Ltd. engages in the research, development, manufacture, and sale of medical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 69 full-time employees. The company went IPO on 2011-10-24. The firm has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.
See Also
What is 3-D Matrix Ltd's Capital Expenditures?
Capital Expenditures
-29.4m
JPY
Based on the financial report for Jan 31, 2026, 3-D Matrix Ltd's Capital Expenditures amounts to -29.4m JPY.
What is 3-D Matrix Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
9%
Over the last year, the Capital Expenditures growth was -629%. The average annual Capital Expenditures growth rates for 3-D Matrix Ltd have been -20% over the past three years , -7% over the past five years , and 9% over the past ten years .
